Dual drug release from stents-will we be happy with thing one and thing two?
Hehrlein
Christoph
C
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation*; D065095:Calcineurin Inhibitors; D049109:Cell Proliferation / Q000187:drug effects; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000473:pathology / Q000517:prevention & control*; D003331:Coronary Vessels / Q000187:drug effects / Q000473:pathology*; D004195:Disease Models, Animal; D004338:Drug Combinations; D006083:Graft Occlusion, Vascular / Q000517:prevention & control; D007166:Immunosuppressive Agents / Q000494:pharmacology; D017239:Paclitaxel / Q000494:pharmacology*; D015607:Stents; D013552:Swine; D016559:Tacrolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D065095:Calcineurin Inhibitors; D020099:Coated Materials, Biocompatible; D004338:Drug Combinations; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D017239:Paclitaxel; D016559:Tacrolimus